


**Amendments to the Claims:**

This listing of claims will replace all prior versions, and listings, of claims in the application:

**Listing of Claims:**

Claims 1-13 (canceled)

Claim 14 (new) A quinazoline compound of formula



wherein

R<sub>a</sub> denotes a hydrogen atom or a C<sub>1-4</sub>-alkyl group,

R<sub>b</sub> denotes a phenyl, benzyl or 1-phenylethyl group wherein the phenyl nucleus is substituted in each case by the groups R<sub>1</sub> to R<sub>3</sub>, whilst

R<sub>1</sub> and R<sub>2</sub>, which may be identical or different, in each case denote a hydrogen, fluorine, chlorine, bromine or iodine atom,

a C<sub>1-4</sub>-alkyl, hydroxy, C<sub>1-4</sub>-alkoxy, C<sub>3-6</sub>-cycloalkyl, C<sub>4-6</sub>-cycloalkoxy, C<sub>2-5</sub>-alkenyl or C<sub>2-5</sub>-alkynyl group,

an aryl, aryloxy, arylmethyl or arylmethoxy group,

a C<sub>3-5</sub>-alkenyloxy or C<sub>3-5</sub>-alkynyoxy group, whilst the unsaturated moiety may not be linked to the oxygen atom,

a C<sub>1-4</sub>-alkylsulfenyl, C<sub>1-4</sub>-alkylsulfinyl, C<sub>1-4</sub>-alkylsulfonyl, C<sub>1-4</sub>-alkylsulfonyloxy, trifluoromethylsulfenyl, trifluoromethylsulfinyl or trifluoromethylsulfonyl group,

a methyl or methoxy group substituted by 1 to 3 fluorine atoms,

an ethyl or ethoxy group substituted by 1 to 5 fluorine atoms,

a cyano or nitro group or an amino group optionally substituted by one or two C<sub>1-4</sub>-alkyl groups, wherein the substituents may be identical or different, or

R<sub>1</sub> together with R<sub>2</sub>, if they are bound to adjacent carbon atoms, denote a -CH=CH-CH=CH group and

R<sub>3</sub> denotes a hydrogen, fluorine, chlorine or bromine atom,

a C<sub>1-4</sub>-alkyl, trifluoromethyl or C<sub>1-4</sub>-alkoxy group,

X denotes a nitrogen atom,

A denotes an imino group optionally substituted by a C<sub>1-4</sub>-alkyl group,

B denotes a carbonyl group,

C denotes a -CH=C=CH-, >C=CH<sub>2</sub> or -CH=CH- group which may be substituted in each case by one or two methyl groups or by a trifluoromethyl group,

an -C≡C- group or

a -CH=CH-CH=CH- group optionally substituted by 1 to 4 methyl groups or by a trifluoromethyl group,

D denotes an alkylene group wherein the alkylene moiety contains 1 to 8 carbon atoms and additionally 1 to 4 hydrogen atoms in the alkylene moiety may be replaced by fluorine atoms,

E denotes an amino, C<sub>1-4</sub>-alkylamino or di-(C<sub>1-4</sub>-alkyl)-amino group wherein the alkyl moieties may be identical or different,

a C<sub>2-4</sub>-alkylamino group wherein the alkyl moiety is substituted in β-, γ-, or δ-position with regard to the nitrogen atom of the amino group by the group R<sub>5</sub>, whilst

R<sub>5</sub> denotes a hydroxy, C<sub>1-4</sub>-alkoxy, amino, C<sub>1-4</sub>-alkylamino or di-(C<sub>1-4</sub>-alkyl)-amino group,

an N-(C<sub>1-4</sub>-alkyl)-N-(C<sub>2-4</sub>-alkyl)-amino group wherein the C<sub>2-4</sub>-alkyl moiety is substituted in β-, γ-, or δ-position with regard to the nitrogen atom of the amino group by the group R<sub>5</sub>, whilst R<sub>5</sub> is as hereinbefore defined,

a di-(C<sub>2-4</sub>-alkyl)-amino group wherein the two C<sub>2-4</sub>-alkyl moieties are substituted in each case in β-, γ-, or δ-position with regard to the nitrogen atom of the amino group by the group R<sub>5</sub>, whilst the substituents may be identical or different and R<sub>5</sub> is as hereinbefore defined,

a C<sub>3-7</sub>-cycloalkylamino or C<sub>3-7</sub>-cycloalkyl-C<sub>1-3</sub>-alkylamino group wherein in each case the nitrogen atom may be substituted by a further C<sub>1-4</sub>-alkyl group,

R<sub>c</sub> denotes a C<sub>4-7</sub>-cycloalkoxy or C<sub>3-7</sub>-cycloalkyl-C<sub>1-6</sub>-alkoxy group wherein the cycloalkyl moiety in each case may be substituted by a C<sub>1-3</sub>-alkyl, hydroxy, C<sub>1-4</sub>-alkoxy, amino, C<sub>1-4</sub>-alkylamino, di-(C<sub>1-4</sub>-alkyl)-amino, hydroxy-C<sub>1-2</sub>-alkyl, C<sub>1-4</sub>-alkoxy-C<sub>1-2</sub>-alkyl, amino-C<sub>1-2</sub>-alkyl, C<sub>1-4</sub>-alkylamino-C<sub>1-2</sub>-alkyl, or di-(C<sub>1-4</sub>-alkyl)-amino-C<sub>1-2</sub>-alkyl group, whilst the abovementioned monosubstituted cycloalkyl moieties may additionally be substituted by a C<sub>1-3</sub>-alkyl group,

whilst

by the aryl moieties mentioned in the definition of the abovementioned groups is meant a phenyl group which in each case may be monosubstituted by R<sub>7</sub>, mono-, di- or trisubstituted by R<sub>8</sub> or monosubstituted by R<sub>7</sub> and additionally mono- or disubstituted by R<sub>8</sub>, wherein the substituents may be identical or different and

R<sub>7</sub> denotes a cyano, carboxy, C<sub>1-4</sub>-alkoxycarbonyl, aminocarbonyl, C<sub>1-4</sub>-alkylaminocarbonyl, di-(C<sub>1-4</sub>-alkyl)-aminocarbonyl, C<sub>1-4</sub>-alkylsulfenyl, C<sub>1-4</sub>-alkylsulfinyl, C<sub>1-4</sub>-alkylsulfonyl, hydroxy, C<sub>1-4</sub>-alkylsulfonyloxy, trifluoromethoxy, nitro, amino, C<sub>1-4</sub>-alkylamino, di-(C<sub>1-4</sub>-alkyl)-amino, C<sub>1-4</sub>-alkyl-carbonylamino, N-(C<sub>1-4</sub>-alkyl)-C<sub>1-4</sub>-alkylcarbonylamino, C<sub>1-4</sub>-alkylsulfonylamino, N-(C<sub>1-4</sub>-alkyl)-C<sub>1-4</sub>-alkylsulfonylamino, aminosulfonyl, C<sub>1-4</sub>-alkylaminosulfonyl or di-(C<sub>1-4</sub>-alkyl)-aminosulfonyl group, and

R<sub>8</sub> denotes a fluorine, chlorine, bromine or iodine atom, a C<sub>1-4</sub>-alkyl, trifluoromethyl or C<sub>1-4</sub>-alkoxy group or

two groups R<sub>8</sub>, if they are bound to adjacent carbon atoms, together denote a C<sub>3-5</sub>-alkylene or 1,3-butadien-1,4-ylene group,

or the tautomers, or stereoisomers or pharmaceutically acceptable salts thereof.

Claim 15 (new) The quinazoline of formula I according to claim 14, wherein

R<sub>a</sub> denotes a hydrogen atom,

R<sub>b</sub> denotes a phenyl, benzyl or 1-phenylethyl group wherein the phenyl nucleus is substituted in each case by the groups R<sub>1</sub> to R<sub>3</sub>, whilst

R<sub>1</sub> and R<sub>2</sub>, which may be identical or different, in each case denote a hydrogen, fluorine, chlorine, bromine or iodine atom,

a C<sub>1-4</sub>-alkyl, hydroxy, C<sub>1-4</sub>-alkoxy, C<sub>3-6</sub>-cycloalkyl, C<sub>4-6</sub>-cycloalkoxy, C<sub>2-5</sub>-alkenyl or C<sub>2-5</sub>-alkynyl group,

an aryl, aryloxy, arylmethyl or arylmethoxy group,

a methyl or methoxy group substituted by 1 to 3 fluorine atoms,

a cyano or nitro group and

R<sub>3</sub> denotes a hydrogen, fluorine, chlorine or bromine atom,

a C<sub>1-4</sub>-alkyl, trifluoromethyl or C<sub>1-4</sub>-alkoxy group,

X denotes a nitrogen atom,

A denotes an imino group,

B denotes a carbonyl group,

C denotes a -CH=C=CH-, >C=CH<sub>2</sub> or -CH=CH- group,

an -C≡C- or -CH=CH-CH=CH- group,

D denotes an alkylene group wherein the alkylene moiety in each case contains 1 to 4 carbon atoms and additionally 1 to 4 hydrogen atoms in the alkylene moiety may be replaced by fluorine atoms,

E denotes a di-(C<sub>1-4</sub>-alkyl)-amino group wherein the alkyl moieties may be identical or different,

an N-(C<sub>1-4</sub>-alkyl)-N-(C<sub>2-4</sub>-alkyl)-amino group wherein the C<sub>2-4</sub>-alkyl moiety is substituted in β-, γ-, or δ-position with regard to the nitrogen atom of the amino group by the group R<sub>5</sub>, where

R<sub>5</sub> denotes a hydroxy, C<sub>1-4</sub>-alkoxy or di-(C<sub>1-4</sub>-alkyl)-amino group,

a di-(C<sub>2-4</sub>-alkyl)-amino group wherein the two C<sub>2-4</sub>-alkyl moieties in each case are substituted in β-, γ-, or δ-position with regard to the nitrogen atom of the amino group by the group R<sub>5</sub>, wherein the substituents may be identical or different and R<sub>5</sub> is as hereinbefore defined,

a C<sub>3-7</sub>-cycloalkylamino or C<sub>3-7</sub>-cycloalkyl-C<sub>1-3</sub>-alkylamino group wherein in each case the nitrogen atom is substituted by a further C<sub>1-4</sub>-alkyl group,

R<sub>c</sub> denotes a C<sub>4-7</sub>-cycloalkoxy or C<sub>3-7</sub>-cycloalkyl-C<sub>1-6</sub>-alkoxy group wherein the cycloalkyl moiety in each case may be substituted by a C<sub>1-3</sub>-alkyl, hydroxy, C<sub>1-4</sub>-alkoxy, di-(C<sub>1-4</sub>-alkyl)-amino, hydroxy-C<sub>1-2</sub>-alkyl, C<sub>1-4</sub>-alkoxy-C<sub>1-2</sub>-alkyl, or di-(C<sub>1-4</sub>-alkyl)-amino-C<sub>1-2</sub>-alkyl group, whilst the abovementioned monosubstituted cycloalkyl moieties may additionally be substituted by a C<sub>1-3</sub>-alkyl group, , whilst

by the aryl moieties mentioned in the definition of the abovementioned groups is meant a phenyl group which may in each case be monosubstituted by R<sub>7</sub>, mono-, di- or trisubstituted by R<sub>8</sub> or monosubstituted by R<sub>7</sub> and additionally mono- or disubstituted by R<sub>8</sub>, wherein the substituents may be identical or different and

R<sub>7</sub> denotes a cyano, carboxy, C<sub>1-4</sub>-alkoxycarbonyl, aminocarbonyl, C<sub>1-4</sub>-alkylaminocarbonyl, di-(C<sub>1-4</sub>-alkyl)-aminocarbonyl, C<sub>1-4</sub>-alkylsulfonyl, C<sub>1-4</sub>-alkylsulfinyl, C<sub>1-4</sub>-alkylsulfonyl, hydroxy, C<sub>1-4</sub>-alkylsulfonyloxy, trifluoromethoxy, nitro, amino, C<sub>1-4</sub>-alkylamino, di-(C<sub>1-4</sub>-alkyl)-amino, C<sub>1-4</sub>-alkyl-carbonylamino, N-(C<sub>1-4</sub>-alkyl)-C<sub>1-4</sub>-alkylcarbonylamino, C<sub>1-4</sub>-alkylsulfonylamino, N-(C<sub>1-4</sub>-alkyl)-C<sub>1-4</sub>-alkylsulfonylamino, aminosulfonyl, C<sub>1-4</sub>-alkylaminosulfonyl or di-(C<sub>1-4</sub>-alkyl)-aminosulfonyl group, and

R<sub>8</sub> denotes a fluorine, chlorine, bromine or iodine atom, a C<sub>1-4</sub>-alkyl, trifluoromethyl or C<sub>1-4</sub>-alkoxy group or

two groups R<sub>8</sub>, if they are bound to adjacent carbon atoms, together denote a C<sub>3-5</sub>-alkylene or 1,3-butadien-1,4-ylene group,

or the tautomers, or stereoisomers or pharmaceutically acceptable salts thereof.

Claim 16 (new) The quinazoline of formula I according to claim 14, wherein

R<sub>a</sub> denotes a hydrogen atom,

R<sub>b</sub> denotes a phenyl, benzyl or 1-phenylethyl group wherein the phenyl nucleus is substituted in each case by the groups R<sub>1</sub> and R<sub>2</sub>, where

R<sub>1</sub> and R<sub>2</sub>, which may be identical or different, in each case denote a hydrogen, fluorine, chlorine or bromine atom,

a methyl, trifluoromethyl or methoxy group,

X denotes a nitrogen atom,

A denotes an imino group,

B denotes a carbonyl group,

C denotes a-CH=CH- group,

an -C≡C- or -CH=CH-CH=CH- group,

D denotes a C<sub>1-4</sub>-alkylene group,

E denotes a di-(C<sub>1-4</sub>-alkyl)-amino group wherein the alkyl moieties may be identical or different,

an N-(C<sub>1-4</sub>-alkyl)-N-(C<sub>2-4</sub>-alkyl)-amino group wherein the C<sub>2-4</sub>-alkyl moiety is substituted in β-, γ-, or δ-position with regard to the nitrogen atom of the amino group by the group R<sub>5</sub>, whilst

R<sub>5</sub> denotes a hydroxy, C<sub>1-3</sub>-alkoxy or di-(C<sub>1-3</sub>-alkyl)-amino group,

a di-(C<sub>2-4</sub>-alkyl)-amino group wherein the two C<sub>2-4</sub>-alkyl moieties in each case are substituted in β-, γ-, or δ-position with regard to the nitrogen atom of the amino group by the group R<sub>5</sub>, wherein the substituents may be identical or different and R<sub>5</sub> is as hereinbefore defined,

a C<sub>3-5</sub>-cycloalkylamino or C<sub>3-5</sub>-cycloalkyl-C<sub>1-3</sub>-alkylamino group wherein in each case the nitrogen atom is substituted by a further C<sub>1-3</sub>-alkyl group,

R<sub>c</sub> denotes a C<sub>4-7</sub>-cycloalkoxy or C<sub>3-7</sub>-cycloalkyl-C<sub>1-4</sub>-alkoxy group wherein the cycloalkyl moiety in each case may be substituted by a C<sub>1-3</sub>-alkyl or C<sub>1-3</sub>-alkoxy group, or the tautomers, or stereoisomers or pharmaceutically acceptable salts thereof.

Claim 17 (new) The quinazoline of formula I according to claim 14, wherein

R<sub>a</sub> denotes a hydrogen atom,

R<sub>b</sub> denotes a phenyl, benzyl or 1-phenylethyl group, whilst the phenyl nucleus is substituted in each case by the radicals R<sub>1</sub> and R<sub>2</sub>, whilst

R<sub>1</sub> and R<sub>2</sub>, which may be identical or different, each denotes a hydrogen, fluorine, chlorine or bromine atom,

X denotes a nitrogen atom,

A denotes an imino group,

B denotes a carbonyl group,

C denotes a -CH=CH-, -C≡C- or-CH=CH-CH=CH- group,

D denotes an C<sub>1-3</sub>-alkylene group,

E denotes a di-(C<sub>1-4</sub>-alkyl)-amino group, wherein the alkyl moieties may be identical or different,

a methylamino or ethylamino group each substituted at the nitrogen atom by a 2-methoxyethyl, 1-methoxy-2-propyl, 2-methoxypropyl, 3-methoxypropyl, cyclopropyl or cyclopropylmethyl group,

a bis-(2-methoxyethyl)amino group,

R<sub>c</sub> denotes a cyclopropylmethoxy, cyclobutylmethoxy, cyclopentylmethoxy or cyclohexylmethoxy group,

a cyclobutyloxy, cyclopentyloxy or cyclohexyloxy group,  
or the tautomers, or stereoisomers or pharmaceutically acceptable salts thereof.

Claim 18 (new) The quinazoline of formula I according to claim 14, wherein

R<sub>a</sub> denotes a hydrogen atom,

R<sub>b</sub> denotes a 1-phenylethyl group or a phenyl group wherein the phenyl nucleus is substituted by the radicals R<sub>1</sub> and R<sub>2</sub>, whilst

R<sub>1</sub> and R<sub>2</sub>, which may be identical or different, each denote a hydrogen, fluorine, chlorine or bromine atom,

X denotes a nitrogen atom,

A denotes an imino group,

B denotes a carbonyl group,

C denotes a -CH=CH-, -C≡C- or -CH=CH-CH=CH- group,

D denotes a methylene group,

E denotes a dimethylamino, diethylamino, Bis(2-methoxyethyl)amino, N-methyl-N-(2-methoxyethyl)amino, N-ethyl-N-(2-methoxyethyl)amino, N-methyl-N-cyclopropylamino, N-methyl-N-cyclopropylmethyl-amino, N-methyl-N-(1-methoxy-2-propyl)amino, N-methyl-N-(2-methoxypropyl)amino or N-methyl-N-(3-methoxypropyl)amino group,

R<sub>c</sub> denotes a cyclopropylmethoxy, cyclobutoxy or cyclopentyloxy group,

or the tautomers, or stereoisomers or pharmaceutically acceptable salts thereof.

Claim 19 (new) The following compound of general formula I according to claim 14:

4-[(3-Chloro-4-fluorophenyl)amino]-6-{[4-(N,N-diethylamino)-1-oxo-2-buten-1-yl]amino}-7-cyclopropylmethoxyquinazoline

or a pharmaceutically acceptable salt thereof.

Claim 20 (new) The physiologically acceptable salt of a compound according to one of claims 14 to 19 with an inorganic or organic acid or base.

Claim 21 (new) A pharmaceutical composition comprising a compound according to claim 20, together with an inert carrier and with or without a diluent.

Claim 22 (new) A method for treating a disease comprising administering a pharmaceutical composition according to claim 21, wherein said disease is selected from the group consisting of: malignant tumors, diseases of the airways and lungs and diseases of the gastrointestinal tract and the bile duct and gall bladder.